Laparoscopic Sleeve Gastrectomy-Induced Decline in Plasma Asprosin and Its Association With Metabolic Recovery

the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR), and lipid profiles, and to compare asprosin concentrations between bariatric patients and healthy normal-weight controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity, Morbid Arachnodactyly Body Weight Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Limb Deformities, Congenital Musculoskeletal Abnormalities Musculoskeletal Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

Shuai Zhao

Yangzhou, None Selected, 225001, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age between 18 and 65 years;
body mass index (BMI) ≥37.5 kg/m², or BMI ≥32.5 kg/m² with at least one obesity-related comorbidity;
availability of complete clinical data and stored plasma samples at preoperative baseline and at 3, 6, and 12 months postoperatively.

Exclusion criteria

history of prior bariatric or gastrointestinal surgery;
active malignancy, chronic inflammatory or infectious disease, or severe hepatic or renal dysfunction;
pregnancy during the study period;
incomplete clinical or biochemical data.

Treatment and study plan

Surgery

Procedure

laparoscopic sleeve gastrectomy

Primary outcomes

Plasma asprosin levels at 3, 6, and 12 months

Time frame: 1 year

Secondary outcomes

BMI at 3, 6, and 12 months

Time frame: 1 year

Other outcomes

Insulin resistance (HOMA-IR) at 3, 6, and 12 months

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Northern Jiangsu People's Hospital

Other

Registry information

Important dates

Study start: 2021
Primary completion: 2025
Study completion: 2025
First posted: Jun 6, 2025
Registry last updated: Jun 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed